CRX-527 as a candidate adjuvant in a recombinant BCG-based malaria vaccine
Asian Pacific Journal of Tropical Biomedicine
;
(12): 1-7, 2024.
Article
Dans Anglais
| WPRIM
| ID: wpr-1030987
ABSTRACT
@#Abstract Objective:
To investigate the role of CRX-527, a Toll-like receptor 4 agonist, as the possible adjuvant for recombinant Mycobacterium bovis Bacillus Calmette-Guerin expressing merozoite surface protein 1C (BCG-MSP-1C).Methods:
The mice were immunized with BCG and BCG-MSP- 1C in the presence and absence of CRX-527. The untreated mice (injected with PBS-T80 only) were the negative control. The ability of CRX-527 to enhance IgG and its subclasses, as well as IL-4 and IFN-γ production in the serum and spleen supernatant was evaluated using ELISA.Results:
Mice immunized with BCG-MSP-1C exhibited the highest production of IgGs, IL-4 and IFN-γ after third immunization. In addition, CRX-527 further promoted the production of total IgG and IgG subclasses as well as IFN-γ and IL-4 in the serum and splenocytes of immunized mice.Conclusions:
CRX-527 has the potential as an adjuvant candidate for the candidate vaccines. Further study is needed to verify appropriate dosage for immunization and its efficacy.
Texte intégral:
Disponible
Indice:
WPRIM (Pacifique occidental)
langue:
Anglais
Texte intégral:
Asian Pacific Journal of Tropical Biomedicine
Année:
2024
Type:
Article
Documents relatifs à ce sujet
MEDLINE
...
LILACS
LIS